Diltiazem Dosing
For acute rate control in supraventricular tachycardia or atrial fibrillation with rapid ventricular response, administer diltiazem 0.25 mg/kg IV (based on actual body weight) over 2 minutes, followed by a continuous infusion of 5-15 mg/hour; for chronic oral therapy, start with 120 mg daily of extended-release formulation and titrate up to a maximum of 360 mg daily in divided or single doses.
Intravenous Dosing
Acute Rate Control (SVT/Atrial Fibrillation)
Initial bolus: 0.25 mg/kg IV (actual body weight) administered over 2 minutes 1, 2
Repeat dosing if needed: If inadequate response after 15 minutes, give a second bolus of 0.35 mg/kg (20-25 mg) over 2 minutes 3
Continuous infusion: 5-10 mg/hour initially, titrate up to maximum 15 mg/hour based on heart rate response 1, 4
Weight-Based vs. Non-Weight-Based Considerations
Recent evidence suggests weight-based dosing (≥0.13 mg/kg) achieves heart rate control faster than fixed 10 mg doses. Patients receiving ≥0.13 mg/kg achieved HR <100 bpm in 169 minutes versus 318 minutes with lower doses, with 61% versus 36% achieving rate control within 4 hours 5. Another study found weight-based dosing resulted in significantly more patients achieving HR <100 bpm (53.5% vs 40.9%) 6.
Clinical pearl: Most emergency departments underdose diltiazem—the majority of patients receive only 10 mg boluses (mean 0.13 mg/kg), which is suboptimal 5.
Oral Dosing
Immediate-Release Formulation
Starting dose: 120 mg daily in divided doses (typically 30 mg four times daily or 60 mg twice daily) 1
Maintenance range: 120-360 mg daily in divided doses 1, 7
Extended-Release Formulation
Starting dose: 120 mg once daily 1
Maintenance range: 120-360 mg once daily 1, 4
Titration: Increase gradually based on response; doses up to 540 mg daily have been studied but 360 mg is the typical maximum 8
Transition from IV to Oral
After achieving acute rate control with IV diltiazem, oral immediate-release diltiazem (typically 30 mg) may be more effective than continuing IV infusion. One study found oral immediate-release had lower treatment failure rates (27% vs 46%) compared to IV continuous infusion at 4 hours 9.
Special Populations
Elderly Patients (≥65 years)
Start at the low end of the dosing range due to decreased hepatic metabolism and clearance 10, 11
Pharmacokinetic changes in elderly:
- Clearance reduced by approximately 40% (13 vs 23 mL/min/kg after 25 mg IV) 12
- Elimination half-life prolonged (4.5-4.7 hours vs 3.3-3.8 hours in younger patients) 12
- Greater blood pressure reduction for same dose (19% vs 8% decrease after 50 mg IV) 12
Recommended approach: Start with 200 mg once daily of extended-release formulation, which has been shown safe and effective in elderly patients aged 65-85 years 13. Can increase to 300 mg once daily if needed.
Hepatic Impairment
Use with extreme caution and reduce doses significantly 10, 11
Diltiazem is extensively metabolized by the liver via CYP3A4. In cirrhotic patients:
- Serum levels increase substantially
- Elimination half-life increases from 5.3 to 7.2 hours 14
- Active metabolite deacetyl-diltiazem levels double 14
Practical approach: Start with 50% of standard dose and monitor closely. The FDA label explicitly warns about increased risk of toxic reactions in hepatic impairment 10.
Renal Impairment
Use with caution but dose adjustment less critical than with hepatic impairment 10
Diltiazem is primarily hepatically eliminated, but the kidneys play a role. Monitor renal function, especially in elderly patients who are more likely to have decreased renal function 10.
Critical Precautions
Absolute Contraindications
- AV block greater than first degree (without pacemaker)
- Sick sinus node dysfunction (without pacemaker)
- Decompensated systolic heart failure or severe LV dysfunction
- Hypotension
- Cardiogenic shock
- WPW syndrome with atrial fibrillation/flutter 1, 2, 1
Drug Interactions
CYP3A4 substrate and moderate inhibitor 1, 2
Critical interactions requiring dose adjustment:
- Statins: Limit simvastatin to ≤10 mg daily and lovastatin to ≤20 mg daily when combined with diltiazem 15, 11
- Beta-blockers: Risk of profound bradycardia and AV block when combined; use with extreme caution 10
- Digoxin: Monitor levels closely; diltiazem increases digoxin exposure 1
Monitoring Parameters
During IV administration:
- Continuous ECG monitoring for bradycardia, AV block, QRS/QTc changes
- Blood pressure every 5-15 minutes initially
- Heart rate response
During oral therapy:
- Baseline and periodic ECG (every 3-6 months)
- Liver function tests (diltiazem can cause hepatotoxicity, though rare) 1
- Blood pressure and heart rate at each visit
Common Pitfalls
Underdosing in acute settings: Using fixed 10 mg boluses instead of weight-based 0.25 mg/kg leads to suboptimal rate control 5
Combining with beta-blockers without caution: The longer half-life of both drugs means their effects overlap, risking profound bradycardia 3
Using in pre-excited atrial fibrillation: AV nodal blockers can paradoxically accelerate ventricular response via the accessory pathway 3, 1
Ignoring hepatic impairment: Failure to reduce doses in cirrhosis leads to drug accumulation and toxicity 14
Inadequate statin dose adjustment: Continuing high-dose simvastatin (>10 mg) or lovastatin (>20 mg) with diltiazem increases rhabdomyolysis risk 15, 11